New Success Story with Enterome, a French company developing bacterial peptides!

Enterome is a clinical-stage company developing off-the-shelf cancer treatments targeting a wide range of tumor types (Glioblastoma, adrenal tumors, non-Hodgkin lymphoma and colorectal cancer). Their Phase 2 programs, EO2463, EO4010 and EO2401, have shown promising efficacy with good safety profiles in over 240 patients.

A huge thank you to Pierre BELICHARD, CEO of Enterome, for sharing this testimonial:

“INITS has been a trusted partner in delivering CMC and clinical supply activities across key development milestones. Their expertise in formulation strategy, Phase 3 readiness, and coordination has been critical to the success of our program. Their proactive approach, strong project management, and clear communication make INITS a highly reliable partner for complex clinical development and supply chain operations.”

At INITS, our expertise extends beyond biologics –  and we’re proud to support companies like Enterome in the production of peptides.

#Peptide #Bacterial #Biotechnology #CMC #ClinicalSupply